Program

 Click here for the full Program including abstract presentations.

 

Thursday 11 October - Day 1

9:00 Opening of the Workshop
 Session 1: Epidemiology of HIV and hepatitis in the CEE countries
9:10Epidemiology of HIV Infection and Treatment in Europe
Teymur Noori, ECDC, Stockholm, Sweden
9:35Update on changes in Hepatitis B and C in CEE countries
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Sczeczin, Poland
10:00How can new diagnostics help to increase the number diagnosed?
Elena Ivanova, MD, PhD, FIND, Geneva, Switzerland
10:25 Country models: what has and what hasn’t worked
Nikoloz Chkhartishvili, MD, MS, PhD, Infectious Diseases, AIDS And Clinical Immunology Research Center, Tbilisi, Georgia
Zahedul Islam, MBA, Alliance for Public Health, Kiev, Ukraine
10:45

Round table Discussion
All chairs and invited speakers

11:10Poster Viewing Session (Posters Nr. 12 - 23) with Coffee and Refreshments
 Session 2: Challenges in HIV and Viral Hepatitis
11:40Hepatitis Delta: what are the new developments, what are the challenges?
Cihan Yurdaydin, MD, Ankara University Medical Centre, Ankara, Turkey
12:05HIV & women's health: do we have any game changers here?
Mariana Mardarescu, MD, PhD, Institute for Infectious Disease M. Bals, Bucharest, Romania
12:30 Round table discussion
12:45 Group picture and Lunch
 Special session: Improving care of treatment-experienced patients
13:45Approach to managing treatment-experienced patients
Jonathan Schapiro, MD, Sheba Medical Center, Tel Aviv, Israel
14:00 

Utilizing new diagnostics, web-tools and drugs for optimal care of treatment-experienced patients. A case-based joint presentation
Jonathan Schapiro, MD, Sheba Medical Center, Tel Aviv, Israel
David Back, PhD, University of Liverpool, Liverpool, United Kingdom

14:15 Treatment-experienced patients in Central and Eastern Europe – What needs to be done?
Viktor Aster, MD, PhD, Charles University, Prague, Czech Republic
14:30 Discussion
 Session 3: Switching HIV therapy: considerations and strategies
14:45 Clinical considerations in switching antiretroviral therapy
David Jilich, MD, HIV Centre Prague, Prague, Czech Republic
15:05Clinical Case Discussion: Switching HIV Therapy
Pavel Khaykin, MD, MainFachArzt, Frankfurt, Germany
15:25Discussion
15:35Poster Viewing Session (Posters Nr. 24 - 35) with Coffee and Refreshments
 Session 4: Abstract-driven presentations
16:05Real-life effectiveness of ledipasvir/sofosbuvir regimen and factors associated with retention in care among HIV/HCV co-infected PWID in Ukraine
Tetyana Kyrychenko, Ukraine
 #1
16:15Possible misclassification of HIV transmission between men:  results of phylogenetic analysis
Natia Dvali, Georgia
 #2
16:25Epidemiology of HIV in the Baltic countries (Estonia, Latvia, Lithuania)
Saulius Caplinskas, Lithuania
 #3
16:35Socio-demographic risk factors for high HEV seroprevalence among liver transplant recipients in Croatia
Anna Mrzljak, Croatia
 #4
16:45Spontaneous HCV clearance in HCV/HIV coinfected patients from AIDS Center Prague
Viktor Aster, Czech Republic
 #5
 17:00Industry-sponsored Symposium
 18:00End of day 1
 18:15Departure for the boat
 19:15Workshop Dinner, Klub Lavka - Charles Bridge (pre-registration required)
 

Friday 12 October - Day 2

 8:30Industry-sponsored Symposium
  
 Session 5: Management of hepatitis C
9:30 Critical assessment of the global epidemiology of HCV (how reliable is the global HCV prevalence data)
Peter Ferenci, MD, University of Vienna, Vienna, Austria
09:55 Liver transplantation for HCV and HBV in The Czech Republic
Soňa Fraňková, MD, PhD, IKEM Prague transplant center, Prague, Czech Republic
10:20

Case Study: The changing IV drug use problem/pattern and what that means to the epidemic
Mojca Maticic, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia

10:45The EpiTer-2 database
Robert Flisiak, MD, PhD, Medical University of Bialystok, Bialystok, Poland
11:05Discussion
11:15Poster Viewing Session (Posters Nr. 36 - 47) with Coffee and Refreshments
 Session 6: Management of hepatitis B
11:45Hepatitis B cure strategies: how far are we?
Heiner Wedemeyer, MD, University Clinic Essen, Essen, Germany
 Abstract-driven presentations
12:10Mortality and causes of death among HIV/HCV co-infected persons in the Eastern European country of Georgia
Akaki Abutidze, Georgia

 #6

12:20HCV resistance-associated variants among HCV treatment naïve HIV-coinfected patients in Ukraine. A pilot study
Marta Vasylyev, Ukraine
 #7
12:30Lunch
 Session 7: Hot topics in HIV and hepatitis
13:30New delivery systems and long acting antiretroviral drugs
David Back, PhD, University of Liverpool, Liverpool, United Kingdom
13:55HIV PreP
Pep Coll, MD, AIDS Research Institute Irsi Caixa, Badalona, Spain
 Abstract presentations
14:20Early results of pre-exposure prophylaxis program in Georgia
Nikoloz Chkhartishvili, Georgia
 #8
14:30The Regression of Liver Fibrosis in HCV Cirrhotic Patients Who Registered SVR after DAA Therapy
Anca Leustean, Romania
 #9
14:40

Approaches to providing hepatitis C viremia testing to people who inject drugs in Georgia
Maia Japaridze, Georgia

 #10
14:50Insulin-like growth factor and platelet-derived growth factor in liver cells of patients with chronic hepatitis C at different stages of fibrosis
Igor Tikhonov, Russia
 #11
15:00End of meeting